JD Bagert
Director, R&D AstraZeneca
Experienced and innovative leader in biologics engineering and drug development, with a focus on multispecific antibodies and a track record of advancing complex biologics from concept to clinic.
Seminars
Thursday 17th September 2026
Where Design Meets Biology: Engineering Multispecific TCEs & ADCs to Expand Therapeutic Index
10:00 am
- Leveraging combinatorial screening platforms for optimizing multispecific modalities
- Increasing tumor selectivity through novel conditionally active T-cell engagers
- Engineering logic-gated bispecific ADCs for enhanced target coverage or tumor selectivity
